Prospective, Multi-centre, Non-Interventional Study to Investigate the Effectiveness of REKOVELLE® for Ovarian Stimulation for Asian Women in Real World Settings
NCT ID: NCT06561958
Last Updated: 2025-09-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1500 participants
OBSERVATIONAL
2024-08-27
2027-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Assess the Patterns of Use of REKOVELLE® in Naïve Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures
NCT03393780
REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)
NCT06545877
Study to Assess the Design of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures in Routine Clinical Practice
NCT04503707
Trial to Assess the Pattern of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice
NCT05499052
A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.
NCT03564509
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
REKOVELLE
Participants prescribed REKOVELLE for the first time for controlled ovarian stimulation.
REKOVELLE
Individualised dosing regiment of REKOVELLE in routine clinical practice.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
REKOVELLE
Individualised dosing regiment of REKOVELLE in routine clinical practice.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Serum AMH level \>0.5 ng / mL (with the latest result tested within 12 months)
* Who are first time prescribed REKOVELLE for their ovarian stimulation and IVF or ICSI treatment cycle using fresh or frozen ejaculated sperm from male partner or sperm donor (if applicable)
* Willing and able to provide written informed consent
Exclusion Criteria
* Participating in an interventional clinical trial in which any medication treatment is mandated
* Women with a contraindication for prescription of REKOVELLE treatment
* Oocyte donors
* Undergoing ovarian stimulation for fertility preservation
20 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ferring Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Compliance
Role: STUDY_DIRECTOR
Ferring Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ferring Investigational Site
Chiba, Chiba, Japan
Ferring Investigational Site
Fukuoka, Fukuoka, Japan
Ferring Investigational Site
Kitakyushu, Fukuoka, Japan
Ferring Investigational Site
Takasaki, Gunma, Japan
Ferring Investigational Site
Hiroshima, Hiroshima, Japan
Ferring Investigational Site
Bunkyō City, Japan, Japan
Ferring Investigational Site
Tokyo, Tokyo, Japan
Ferring Investigational Site
Hiroshima, , Japan
Ferring Investigational Site
Hokkaido, , Japan
Ferring Investigational Site
Hyōgo, , Japan
Ferring Investigational Site
Osaka, , Japan
Ferring Investigational Site
Osaka, , Japan
Ferring Investigational Site
Saitama, , Japan
Ferring Investigational Site
Busan, Busan, South Korea
Ferring Investigational Site
Daegu, Daegu, South Korea
Ferring Investigational Site
Seongnam-si, Seongnam, South Korea
Ferring Investigational Site
Busan, , South Korea
Maria Fertility Hospital
Seoul, , South Korea
Ferring Investigational Site
Tainan City, Tainan, Taiwan
Ferring Investigational Site
Tainan City, Tainan, Taiwan
Ferring Investigational Site
Taoyuan District, Taoyuan, Taiwan
Ferring Investigational Site
Taichung, , Taiwan
Ferring Investigational Site
Taipei, , Taiwan
Ferring Investigational Site
Taipei, , Taiwan
Naresuan University Hospital
Phitsanulok, Muang, Thailand
Ramathibodi Hospital
Bangkok, Ratchathewi, Thailand
Ferring Investigational Site
Bangkok, , Thailand
Ferring Investigational Site
Hanoi, Hanoi, Vietnam
Ferring Investigational Site
Ho Chi Minh City, Ho Chi Minh City, Vietnam
Ferring Investigational Site
Ho Chi Minh City, Ho Chi Minh City, Vietnam
Ferring Investigational Site
Huế, Huế, Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Global Clinical Compliance
Role: primary
Global Clinical Compliance
Role: primary
Global Clinical Compliance
Role: primary
Global Clinical Compliance
Role: primary
Global Clinical Compliance
Role: primary
Global Clinical Compliance
Role: primary
Global Clinical Compliance
Role: primary
Global Clinical Compliance
Role: primary
Global Clinical Compliance
Role: primary
Global Clinical Compliance
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
000430
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.